New research by our scientists may have identified a new way to predict which patients might benefit from certain immunotherapies, and those who likely won’t.
The molecular make-up of lung tumours could help identify patients who might benefit from immunotherapy treatment up front, a new study has found.
Scientists have discovered a new type of immune cell that could predict which lung cancer patients will benefit most from immunotherapy treatment.
Targeted treatment up front improves survival for advanced prostate cancer, and we predict a change in thinking for precision cancer medicine.
We speak to Jane Hair, a biobanker involved in the National Lung Matrix Trial, about what her job involves.
We speak to Amanda Watson, research nurse on the National Lung Matrix Trial, about what her job involves.
We speak to Susie Brown, Trial Coordinator on the National Lung Matrix Trial, about what her job involves.
We speak to Cindy Billingham, lead statistician on the National Lung Matrix Trial, about what her job involves.
An experimental blood test could offer a way to detect early signs that patients’ lung cancers will return after treatment.
By tracing genetic chaos over time our scientists may have found a way to help predict lung cancer survival.